The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

Tirzepatide is the first dual-target therapy that activates both GIP and GLP-1 receptors, helping manage blood sugar levels ...

A study of real-world and virtual patients suggests that a less frequent dosing of glucagon-like peptide 1 receptor agonists ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

U.K. regulators issued guidance on Thursday, warning weight loss and diabetes medications may weaken the effectiveness of ...

The widespread adoption of GLP-1 (glucagon-like peptide-1) receptor agonist medications, such as Ozempic and Wegovy, is ...

The Mounjaro 'golden dose' has been explained after doctors issued an urgent warning over the potential deadly hack.

Given the scope of the risk, attention has turned to metabolic hormones that regulate appetite, satiety, and glucose metabolism, particularly glucagon-like peptide-1 (GLP-1). Its appetite ...

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual ...

I know we wanna cheat the system as Americans, we do,” the 53-year-old tells Page Six in an exclusive interview.